New shot shrinks skin cancer before surgery in early trial

NCT ID NCT06422936

Ongoing Disease control Sponsor: Highlight Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called BO-112, injected directly into basal cell skin cancer tumors before they are surgically removed. The goal is to see if the drug is safe and helps shrink or eliminate the cancer. About 60 adults with low- or high-risk basal cell carcinoma will participate, and researchers will check for tumor response at surgery and for recurrence up to 2 years later.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BASAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

basal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BASAL CELL CARCINOMA

Contacts and locations

Locations

Clínica Universitaria de Navarra (CUN)

Madrid, 28027, Spain
Complejo Asistencial Universitario de Salamanca

Salamanca, 37007, Spain
Hadassah Ein Kerem Medical Center

Jerusalem, Israel
Hospital Clínic Barcelona

Barcelona, 08036, Spain
Hospital Universitario 12 de Octubre

Madrid, 28041, Spain
Hospital de Basurto

Bilbao, 48013, Spain
Instituto Valenciano de Oncología (IVO)

Valencia, 46009, Spain
Kaplan Medical Center

Rehovot, 7661041, Israel
Rambam Medical Center

Haifa, Israel
Soroka Medical Center

Beersheba, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.